[Neurotoxicity of beta-amyloid]

Area of Science:

• Neuroscience
• Biochemistry
• Pathology

Context:

• Beta-amyloid (Aβ) peptides are implicated in Alzheimer's disease (AD) pathogenesis.
• Aβ aggregation and neurotoxicity are key areas of research in neurodegenerative diseases.
• The role of peptide racemization in Aβ toxicity remains an active investigation.

Purpose:

• To investigate the neurotoxic potential of racemized beta-amyloid peptides, specifically D-Ser26 beta 25-35.
• To explore the in vitro and in vivo mechanisms by which these modified peptides induce neuronal damage.
• To assess the correlation between beta-structure formation, MTT reduction inhibition, and neurotoxic activity.

Summary:

• Certain beta-amyloid (Aβ) forms, including D-Ser26 beta 25-35, readily adopt beta-structures, form fibrils, and exhibit toxicity to hippocampal neurons and HeLa cells.
• D-Ser26 Aβ 1-40 is converted by brain proteinases to the toxic, proteinase-resistant D-Ser26 Aβ 25-35 fragment.
• Co-injection of Aβ variants with ibotenic acid causes significant CA1 hippocampal neuron loss in rats, correlating with beta-structure and MTT reduction suppression.
• An antibody against D-Ser26 Aβ 25-35 specifically labels degenerated CA1 neurons in AD brains, suggesting its role in disease pathology.

Impact:

• These findings suggest that D-Ser26 beta 25-35 and related peptides, potentially arising from aged insoluble Aβ 1-40, contribute to hippocampal CA1 pyramidal neuron toxicity.
• The study highlights how these modified peptides increase neuronal vulnerability to excitatory amino acids, offering a potential mechanism for AD-related neurodegeneration.
• This research provides a specific molecular target (D-Ser26 beta 25-35) for understanding and potentially treating Alzheimer's disease.